company background image
AGEN

Agenus NasdaqCM:AGEN Stock Report

Last Price

US$1.90

Market Cap

US$537.4m

7D

21.0%

1Y

-64.6%

Updated

26 Jun, 2022

Data

Company Financials +
AGEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AGEN Stock Overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.

Agenus Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agenus
Historical stock prices
Current Share PriceUS$1.90
52 Week HighUS$6.79
52 Week LowUS$1.25
Beta1.25
1 Month Change18.01%
3 Month Change-28.84%
1 Year Change-64.62%
3 Year Change-36.67%
5 Year Change-51.41%
Change since IPO-99.48%

Recent News & Updates

Shareholder Returns

AGENUS BiotechsUS Market
7D21.0%10.3%6.6%
1Y-64.6%-24.3%-18.4%

Return vs Industry: AGEN underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: AGEN underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement12.2%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: AGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AGEN's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994441Garo Armenhttps://www.agenusbio.com

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Agenus Fundamentals Summary

How do Agenus's earnings and revenue compare to its market cap?
AGEN fundamental statistics
Market CapUS$537.43m
Earnings (TTM)-US$18.78m
Revenue (TTM)US$309.89m

1.7x

P/S Ratio

-28.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGEN income statement (TTM)
RevenueUS$309.89m
Cost of RevenueUS$187.28m
Gross ProfitUS$122.61m
Other ExpensesUS$141.39m
Earnings-US$18.78m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.066
Gross Margin39.56%
Net Profit Margin-6.06%
Debt/Equity Ratio51.3%

How did AGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGEN?

Other financial metrics that can be useful for relative valuation.

AGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AGEN's PS Ratio compare to its peers?

AGEN PS Ratio vs Peers
The above table shows the PS ratio for AGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.9x
ABUS Arbutus Biopharma
19.7x-29.5%US$422.4m
CPRX Catalyst Pharmaceuticals
4.4x8.7%US$682.5m
ORGO Organogenesis Holdings
1.4x9.5%US$645.7m
CHRS Coherus BioSciences
1.9x33.8%US$580.7m
AGEN Agenus
1.7x22.1%US$537.4m

Price-To-Sales vs Peers: AGEN is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (6.9x).


Price to Earnings Ratio vs Industry

How does AGEN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: AGEN is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is AGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio4.9x

Price-To-Sales vs Fair Ratio: AGEN is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (4.9x).


Share Price vs Fair Value

What is the Fair Price of AGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGEN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGEN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGEN's revenue (22.1% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: AGEN's revenue (22.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGEN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Agenus performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


5.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AGEN is currently unprofitable.

Growing Profit Margin: AGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare AGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: AGEN has a negative Return on Equity (-90.14%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Agenus's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AGEN's short term assets ($290.5M) exceed its short term liabilities ($163.1M).

Long Term Liabilities: AGEN's short term assets ($290.5M) exceed its long term liabilities ($250.6M).


Debt to Equity History and Analysis

Debt Level: AGEN has more cash than its total debt.

Reducing Debt: AGEN's debt to equity ratio has reduced from 1559.5% to 51.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AGEN has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 1% each year.


Discover healthy companies

Dividend

What is Agenus's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Garo Armen (68 yo)

28.42yrs

Tenure

US$9,757,448

Compensation

Dr. Garo H. Armen, Ph D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. He serves as Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairm...


CEO Compensation Analysis

Compensation vs Market: Garo's total compensation ($USD9.76M) is above average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Garo's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AGEN's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: AGEN's board of directors are seasoned and experienced ( 15.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.2%.


Top Shareholders

Company Information

Agenus Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Agenus Inc.
  • Ticker: AGEN
  • Exchange: NasdaqCM
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$537.432m
  • Shares outstanding: 282.86m
  • Website: https://www.agenusbio.com

Number of Employees


Location

  • Agenus Inc.
  • 3 Forbes Road
  • Lexington
  • Massachusetts
  • 02421-7305
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.